Best Clinical Genomics Companies in Spain
The 41 best Clinical Genomics companies in Spain in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: STAT Diagnostica.
- Mordor Intelligence
- ResearchAndMarkets.com
Ranked: Best Clinical Genomics companies in Spain
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | STAT Diagnostica Provider of a diagnostic platform for molecular diagnostics and immunoassays | $54M | 118 mo ago | — | Jordi Carrera Co-Founder & Managing Director | — | — | 113 patents Microfluidic cartridges for nucleic acid purification and assay automation | — |
| 2 | Veritas Intercontinental Provider of genomic services | $23M | 71 mo ago | 43 | George Church Founder | WordPress Block EditorWordPressMySQL+33 | Top 500k | 2 patents Computational genomic analysis tools on bioinformatics platforms | — |
| 3 | ADmit Therapeutics Provider of diagnostic services for early detection of Alzheimer's disease | $13M | 34 mo ago | 10 | Jordi Gascon Co-Founder | — | — | 18 patents Biomarker-driven nucleic acid diagnostics for Lewy body dementia and Alzheimer risk assessment | — |
| 4 | Biohope Assay solutions for management of kidney transplant patients | $9M | 3 mo ago | 31 | Isabel Portero Founder & CEO | WordPressMySQLPHP+18 | Top 50M | — | — |
| 5 | NIMGenetics Diagnostic solutions based on microarray and next-generation sequencing technologies | $8M | 111 mo ago | 97 | — | Cart FunctionalityWordPressMySQL+31 | Top 5M | — | — |
| 6 | AB-Biotics Developer of probiotic drugs for dental disorders | $7M | 99 mo ago | 34 | Miquel Bonachera Co-Founder & CEO | WordPressPleskMySQL+24 | Top 10M | 145 patents Therapeutic probiotic formulations for gut health, metabolic and infectious disease treatment. | — |
| 7 | Amadix Provider of diagnostic tools to support personalized cancer treatment | $7M | 18 mo ago | 35 | Rocio Arroyo CEO | WordPress Block EditorElementorWordPress+25 | Top 5M | — | — |
| 8 | AptaTargets Provider of therapeutic solutions for ischemic diseases | $3M | 96 mo ago | 10 | Victor Manuel Gonzalez Muñoz Cofounder and Scientific Advisor | — | — | 23 patents TLR4‑targeted aptamer therapeutics for inflammatory and ischemic stroke treatments | — |
| 9 | Made of Genes Genomics platform for acquiring, storing, and sharing personal genomic information | $3M | 30 mo ago | 20 | — | WordPressMySQLPHP+25 | Top 50M | — | — |
| 10 | Transbiomed Provider of genomics and proteomics based molecular diagnostics solutions | $2M | 186 mo ago | — | Andreas Doll Co-Founder | — | — | — | — |
| 11 | MicroViable Therapeutics Developer of next-generation biotherapeutic products for various diseases | $2M | 52 mo ago | 7 | — | WordPressMySQLPHP+24 | Top 50M | 3 patents Purifying and formulating fecal microbiome therapeutics for human health applications | 1 partnership |
| 12 | GoodGut Diagnosis and treatment of digestive diseases based on intestinal microbiota analysis | $900K | 127 mo ago | 12 | Xavier Aldeguer Co Founder | WordPressPleskMySQL+26 | Top 10M | 43 patents Microbiome-based non‑invasive diagnostics and therapeutic kits for colorectal disease | 1 award |
| 13 | Pangaea Biotech Provider of drug development and molecular diagnostics services on cancer treatment | $298K | 104 mo ago | 55 | — | WordPressMySQLPHP+22 | Top 10M | 104 patents Molecular diagnostics and targeted oncology therapeutics using nucleic acids and luminescent assays | 1 award |
| 14 | Qgenomics Provider of genomic research and diagnostics services for research purposes | $297K | 62 mo ago | — | Lluis Armengol CEO and Scientific Director | WordPressAwesompleteMySQL+18 | Top 10M | — | — |
| 15 | Xenopat Developing xenograft models of cancer for drug development and personalized treatment selection | $158K | 68 mo ago | 4 | Alberto Villanueva Co-Founder | — | — | — | — |
| 16 | Imegen Provider of genetic tests for the detection of various disease conditions | $140K | 110 mo ago | 65 | Manuel Alonso Founder | — | — | — | — |
Top 12 Clinical Genomics companies in Spain
#1
Seed · Tres Cantos, Community of Madrid · founded 2015 · 31 employees$8.5Mraised▾
Biohope develops assay solutions for the management of organ rejection in kidney transplant patients. Its flagship product is a 3D-cell culture that enables physicians to tailor immunosuppressants for renal transplant patients. This assay can be used to prescribe a treatment regimen that prevents organ rejection, and adverse immune reactions due to overuse of immunosuppressants.
- May 2026Seed—
- Jun 2019Grant (prize money)$4.4M
- Jan 2017Grant (prize money)$4M
- Jun 2016Grant (prize money)—
#2
Series A · Madrid, Community of Madrid · founded 2010 · 35 employees$6.9Mraised▾
Provider of diagnostic tools to support personalized cancer treatment. The company has developed prognostic, diagnostic, and predictive tests for lung cancer, colorectal cancer, and prostate cancer. Its colon cancer test ColoFast is a blood-based miRNA test for early detection of colon cancer. It is also developing DiagnoLung which is a blood-based ELISA test that measures the level of three protein biomarkers to screen high-risk patients for non-small-cell lung cancer.
- Feb 2025Venture Debt$15.6M
- Aug 2022Grant (prize money)$2.6M
- Jun 2021Grant (prize money)$3.4M
- Oct 2020Grant (prize money)$152.1K
#3
Series A · Barcelona, Catalonia · founded 2017 · 10 employees$12.9Mraised▾
Provider of diagnostic services for early detection of Alzheimer's disease. The company is developing diagnostic tests by using next-generation sequencing analysis for the detection of biomarkers β-amyloid nor tau. The test is based on an epigenetic analysis in blood samples, covering the analysis of a large number of methylcytosines in mtDNA.
- Oct 2023Series A$5.7M
- Jan 2021Grant (prize money)$3M
- Aug 2020Series A$5M
- Mar 2019Seed$2.3M
#4
Seed · Barcelona, Catalonia · founded 2015 · 20 employees$2.9Mraised▾
Genomics platform for acquiring, storing, and sharing personal genomic information. Genomcore provides end-customers a secure and compliant genomics platform for acquiring, storing, and sharing personal genomic information for its use in clinical and non-clinical applications. The company provides DNA sequencing services and computing services for genomic analysis. Users can obtain, analyze and manage their complete genomic sequence from the company's cloud platform.
- Feb 2024Seed—
- Jul 2020Seed$2.7M
- Jun 2015Seed$100K
- Feb 2015Seed$102K
#5
Series C · Barcelona, Catalonia · founded 2010$53.7Mraised▾
Provider of a diagnostic platform for molecular diagnostics and immunoassays. The proprietary DiagCore comprises an Analyzer that runs on consumable DiagCore cartridges. The STAT-Molecular cartridge automates sample homogenization, cell disruption, nucleic acid purification and delivers up to 50-plex target detection employing qPCR. This test cartridge is designed to automate molecular assays in the fields of infectious diseases, oncology, coagulation, prenatal, inherited diseases, or companion diagnostics. It offers test cartridges designed to automate immunoassays for critical care markers such as Procalcitonin (Sepsis), Troponin (AMI), Ngal (AKI), C-reactive protein (Inflammation), hCG (pregnancy), among others.
- Oct 2016Series C—
- Apr 2016Series C$28.5M
- May 2013Series B$22.3M
- 2011Series A$2.9M
#6
Acquired · Madrid, Community of Madrid · founded 2014 · 43 employees$23.4Mraised▾
Veritas provides genomic services. The company provides genetic testing and genetic counseling services. The company offers a range of genomic testing services for health, newborn hereditary disease risk, cancer diagnosis, pharmacogenetics, and others.
- Sep 2020Series B$5.9M
#7
Acquired · Barcelona, Catalonia · founded 2004 · 34 employees$7.4Mraised▾
Developer of probiotic drugs for dental disorders. It also offers nutraceuticals for the pharmaceutical and food sectors. The company has a portfolio of 21 probiotic products in various categories including cardiometabolic, oral care, pediatrics, gastrointestinal health, gynecology, urology, dermatology, and immunology. It develops drugs for CNS disorders. It also offers services in genetic analyses for conducting pharmacogenetic studies.
- May 2018Post IPO—
- Mar 2018Grant (prize money)$61.6K
- Oct 2017Grant (prize money)$59K
- Jan 2017Grant (prize money)$52.8K
#8
Acquired · Madrid, Community of Madrid · founded 2007 · 97 employees$7.6Mraised▾
Diagnostic solutions based on microarray and next-generation sequencing technologies. The company develops products for both the clinical and research markets. It has three product families for clinical diagnostics TRISONIM, a non-invasive prenatal test for the most commonly diagnosed fetal abnormalities KARYONIM, a range of products for invasive fetal and neonatal testing for chromosomal abnormalities and ONCONIM, which contains one test for BRCA testing, and two gene panels for enabling precision medicine in cancer patients. In addition, NIMGenetics has NIMFISH which is a range of customized FISH probes and EXONIM for whole exome sequencing. NIMGenetics is certified by Life Technologies (now ThermoFisher) for exome sequencing.
- May 2017Series A$7.6M
- Jan 2017Grant (prize money)$260.9K
#9
Seed · Gijon, Asturias · founded 2016 · 7 employees$1.6Mraised▾
Developer of next-generation biotherapeutic products for various diseases. The company develops novel technologies and next-generation biotherapeutic products by harnessing the treasure of the human microbiota generating innovative solutions that enable to address unmet challenges in human diseases. The product pipeline has drugs for Autism Spectrum Disorder, Crohn´s disease, Atopic Dermatitis, longevity, and sports performance
- Apr 2022Seed$1.6M
#10
Series A · Madrid, Community of Madrid · founded 2014 · 10 employees$3Mraised▾
AptaTargets is a provider of therapeutic solutions for ischemic diseases. It has developed ApTOLL product that consists of DNA aptamers with a specific 3D conformation. It will enable TL-4 antagonistic response for controlling the inflammatory response. The first application is the treatment of ischemic stroke. The candidate is currently completing preclinical studies.
- Aug 2018Grant (prize money)—
- May 2017Series A$3M
#11
Deadpooled · Barcelona, Catalonia · founded 2007$1.6Mraised▾
Transbiomed is a provider of genomics and proteomics-based molecular diagnostics solutions. It has developed products through biomarker discovery programs. Flagship product is for the diagnosis of prostrate cancer using a proprietary panel of biomarkers that is administered in conjunction with a standard PSA test.
- Feb 2011Series A$1.6M
#12
Acquired · Girona, Catalonia · founded 2014 · 12 employees$900.2Kraised▾
GoodGut is focussed on diagnosis and treatment of digestive diseases based on a know -how that conceives the intestinal microbiota as a determinant factor for digestive diseases development. GoodGut is a spin-off initiative of the University of Girona (UdG) and the Biomedical Research Institute of Girona. The main GoodGut objective is to offer technological instruments for a faster, more reliable and cost-effective digestive diseases diagnosis than the existing methods. At the same time, GoodGut wants to provide therapy for improving the life quality of patients with delicated digestive health. They are currently developing RAID-CRC (an automated stool-based assay to detect microbiological markers), a prediagnostic test for colorectal cancer, and PREVIPECT, a prebiotic for irritable bowel syndrome.
- Jan 2016Angel$667.5K
- Oct 2014Seed$232.7K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Clinical Genomics coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
How research on Diagnostics is moving in Spain
A read on the academic research around Diagnostics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,258 Spain-affiliated papers.
- Ministry of Health175
- Centro de Investigación Biomédica en Red de Cáncer128
- Instituto de Salud Carlos III58
- Universitat de Barcelona49
- Barcelona Institute for Global Health47
- Liquid biopsy11→50
- Biopsy1→15
- Point-of-care testing5→15
- Biomarker5→14
- Lung cancer1→10
- Liquid biopsy24→135
- Biopsy4→46
- Point-of-care testing16→54
- Biomarker7→43
- Internal medicine10→45
- Liquid biopsy10→40
- Intensive care medicine2→13
- Biomarker3→13
- Point-of-care testing30→40
- Oncology2→12
Where diagnostics is researched across Spain
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.